Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives

被引:16
作者
De Mello, Ramon Andrade Bezerra [1 ,2 ,3 ]
Voscaboinik, Rafael [1 ]
Luciano, Joao Vittor Pires [2 ]
Cremonese, Rafaela Vilela [2 ]
Amaral, Giovanna Araujo [1 ]
Castelo-Branco, Pedro [4 ]
Antoniou, Georgios [4 ]
机构
[1] Univ Fed Sao Paulo UNIFESP, Hosp Sao Paulo, Escola Paulista Med, Div Med Oncol, BR-04023900 Sao Paulo, Brazil
[2] Univ Nove Julho, Fac Med, BR-04023900 Sao Paulo, Brazil
[3] Hosp 9 Julho, Div Med Oncol, Ctr Med Especialidades, BR-01409002 Sao Paulo, Brazil
[4] Univ Algarve, Fac Med & Biomed Sci FMCB, Campus Gambelas, P-8003139 Faro, Portugal
关键词
immunotherapy; advanced lung cancer; durvalumab; pembrolizumab; atezolizumab; ipilimumab; nivolumab; cemiplimab; PD1; PDL1; anti PD1; anti PDL-1; IMMUNE CHECKPOINT INHIBITORS; OPEN-LABEL; 1ST-LINE NIVOLUMAB; EGFR MUTATION; PEMBROLIZUMAB; CHEMOTHERAPY; DOCETAXEL; EPIDEMIOLOGY; ATEZOLIZUMAB; MULTICENTER;
D O I
10.3390/cancers14010122
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The following paper was developed as a reference for healthcare workers who are looking for information on advanced non-small cell lung cancers that lack driver mutations and their treatment with immunotherapy. The aim of the present study is to provide a reliable data source based on a review of the most current papers on the PD-1/PD-L1 and CTLA-4 inhibitors, as well as their use in medical practice. From a complete literature review, we were able to present in this paper what is most current in the treatment with immunotherapy for advanced non-small cell lung cancer (NSCLC). Especially the use of immunotherapy, particularly inhibitors of PD-1 (programmed cell death protein 1), PDL-1 (programmed cell death protein ligand 1), and CTLA-4 (cytotoxic T-lymphocyte antigen 4). Since 2015, these drugs have transformed the treatment of advanced NSCLC lacking driver mutations, evolving from second-line therapy to first-line, with excellent results. The arrival of new checkpoint inhibitors such as cemiplimab and the use of checkpoint inhibitors earlier in the therapy of advanced and metastatic cancers has been making the future prospects for treating NSCLC lacking driver mutations more favorable and optimistic. In addition, for those patients who have low PDL-1 positivity tumors, the combination of cytotoxic chemotherapy, VEGF inhibitor, and immunotherapy have shown an important improvement in global survival and progression free survival regardless the PDL-1 status. We also explored the effectiveness of adding radiotherapy to immunotherapy and the most current results about this combination. One concern that cannot be overlooked is the safety profile of immune checkpoint inhibitors (ICI) and the most common toxicities are described throughout this paper as well as tumor resistance to ICI.
引用
收藏
页数:14
相关论文
共 70 条
[1]   Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone [J].
Abe, Takanori ;
Saito, Satoshi ;
Iino, Misaki ;
Aoshika, Tomomi ;
Ryuno, Yasuhiro ;
Ohta, Tomohiro ;
Igari, Mitsunobu ;
Hirai, Ryuta ;
Kumazaki, Yu ;
Miura, Yu ;
Kaira, Kyoichi ;
Kagamu, Hiroshi ;
Noda, Shin-ei ;
Kato, Shingo .
THORACIC CANCER, 2021, 12 (02) :245-250
[2]   Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies [J].
Ali, Ayad K. ;
Watson, David E. .
PHARMACOTHERAPY, 2017, 37 (11) :1383-1390
[3]  
[Anonymous], Pembrolizumab Injection United States Prescribing Information
[4]  
[Anonymous], Durvalumab Injection United States Prescribing Information
[5]  
[Anonymous], Nivolumab Injection United States Prescribing Information
[6]  
[Anonymous], Cemiplimab-rwlc Injection United States Prescribing Information
[7]   Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].
Antonia, S. J. ;
Villegas, A. ;
Daniel, D. ;
Vicente, D. ;
Murakami, S. ;
Hui, R. ;
Yokoi, T. ;
Chiappori, A. ;
Lee, K. H. ;
de Wit, M. ;
Cho, B. C. ;
Bourhaba, M. ;
Quantin, X. ;
Tokito, T. ;
Mekhail, T. ;
Planchard, D. ;
Kim, Y. -C. ;
Karapetis, C. S. ;
Hiret, S. ;
Ostoros, G. ;
Kubota, K. ;
Gray, J. E. ;
Paz-Ares, L. ;
de Castro Carpeno, J. ;
Wadsworth, C. ;
Melillo, G. ;
Jiang, H. ;
Huang, Y. ;
Dennis, P. A. ;
Ozguroglu, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929
[8]   Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer A Review [J].
Arbour, Kathryn C. ;
Riely, Gregory J. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (08) :764-774
[9]   Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Borghaei, H. ;
Paz-Ares, L. ;
Horn, L. ;
Spigel, D. R. ;
Steins, M. ;
Ready, N. E. ;
Chow, L. Q. ;
Vokes, E. E. ;
Felip, E. ;
Holgado, E. ;
Barlesi, F. ;
Kohlhaeufl, M. ;
Arrieta, O. ;
Burgio, M. A. ;
Fayette, J. ;
Lena, H. ;
Poddubskaya, E. ;
Gerber, D. E. ;
Gettinger, S. N. ;
Rudin, C. M. ;
Rizvi, N. ;
Crino, L. ;
Blumenschein, G. R. ;
Antonia, S. J. ;
Dorange, C. ;
Harbison, C. T. ;
Finckenstein, F. Graf ;
Brahmer, J. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639
[10]   Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].
Brahmer, Julie ;
Reckamp, Karen L. ;
Baas, Paul ;
Crino, Lucio ;
Eberhardt, Wilfried E. E. ;
Poddubskaya, Elena ;
Antonia, Scott ;
Pluzanski, Adam ;
Vokes, Everett E. ;
Holgado, Esther ;
Waterhouse, David ;
Ready, Neal ;
Gainor, Justin ;
Aren Frontera, Osvaldo ;
Havel, Libor ;
Steins, Martin ;
Garassino, Marina C. ;
Aerts, Joachim G. ;
Domine, Manuel ;
Paz-Ares, Luis ;
Reck, Martin ;
Baudelet, Christine ;
Harbison, Christopher T. ;
Lestini, Brian ;
Spigel, David R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135